SecBot SecBot
SECBOTREPLAY Home › Report › ANVS

ANVS · Annovis Bio reported a wider-than-expected EPS loss of $-0.39 (vs…

Annovis Bio Inc. · PRESS-RELEASE filed Apr 10, 2026 at 08:30 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Apr 10, 2026 at 08:30 ET

Annovis Bio reported a wider-than-expected EPS loss of $-0.39 (vs $-0.36 est) with no revenue, but secured $10M in gross proceeds from a public offering, extending its cash runway to Q2 2027 and fully funding its path to a Phase 3 Alzheimer's data readout and NDA submission for buntanetap.

  • Reported EPS of $-0.39, missing consensus by $-0.03 (-8.3%)
  • No revenue reported for the period
  • Closed $10M underwritten public offering, extending cash runway to Q2 2027
  • Alzheimer's Phase 3 trial 75% enrolled; 6-month symptomatic data readout expected Q1 2027

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access